Citius Pharmaceuticals, Inc. — FY2018 Form 10-K Summary
Reporting period: Fiscal year ended September 30, 2018. The filing is an annual report, not a standalone fourth-quarter report; separate Q4 results are not clearly provided. The company is a pre-revenue specialty pharmaceutical developer focused on Mino-Lok and a topical hemorrhoid-treatment candidate.
Financial performance and position
| Metric | FY2018 | FY2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $6.56 million | $2.94 million |
| General and administrative expense | $6.45 million | $6.06 million |
| Total operating expenses / operating loss | $13.79 million | $9.99 million |
| Net loss | $12.54 million | $10.38 million |
| Net loss per share, basic and diluted | $1.17 | $1.89 |
| Net cash used in operating activities | $11.32 million | $7.97 million |
- Cash and cash equivalents were $9.18 million at September 30, 2018, versus $3.20 million a year earlier. Working capital was $6.88 million.
- Total assets were $31.05 million; total current liabilities were $3.18 million. Stockholders’ equity was $27.87 million, with an accumulated deficit of $40.26 million.
- Current notes payable to related parties totaled $172,970, plus $57,854 accrued related-party interest. The company reported no off-balance-sheet arrangements.
- FY2018 financing activities provided $17.30 million net, principally from equity offerings and warrant exercises. There was no reported revenue or gross margin; operating and net margins are therefore not meaningful.
Changes versus the prior year
- Net loss increased $2.15 million, primarily as R&D expense rose $3.63 million with the Mino-Lok Phase 3 trial underway. Mino-Lok R&D costs were $6.12 million, compared with $2.69 million in FY2017.
- Operating cash use increased $3.35 million. Cash nevertheless rose year over year, supported by $17.30 million of net financing proceeds.
- FY2018 other income included an $818,343 FDA fee refund receivable and a $450,000 gain from reversing an R&D liability accrual. The FDA refund was received October 1, 2018.
- Net loss per share declined despite the larger total loss, as weighted-average shares increased to 10.73 million from 5.48 million.
Business, outlook, risks, and unusual items
- Mino-Lok: The lead candidate is an antibiotic lock solution intended to treat catheter-related bloodstream infections while salvaging infected catheters. The Phase 3 trial began enrolling in February 2018, with a planned 700 patients. The filing reports 20 active enrolling sites as of December 2018, with additional sites in startup or feasibility review. The company had FDA Fast Track and Qualified Infectious Disease Product designations; neither constitutes approval. Previously reported Phase 2b results were from a small study and matched cohort.
- Hemorrhoid candidate: The company shifted from CITI-001 to a reformulated higher-potency steroid/lidocaine candidate, referred to as CITI-002 or Halo-Lido. Further development and clinical work remained planned; no regulatory approval or commercial sales were reported.
- Funding and going concern: The auditor highlighted substantial doubt about the company’s ability to continue as a going concern. Management stated it expected to have capital through June 2019 and planned to raise more; elsewhere the filing states capital was insufficient beyond the first nine months of FY2019. Additional financing was not assured, and the statements include no adjustments for a possible failure to continue as a going concern.
- Capital and dilution: The August 2018 offering generated $8.93 million net and included substantial warrants, including pre-funded warrants exercisable at $0.01. At September 30, 2018, 15.19 million warrant shares and 1.60 million option shares were outstanding; common shares outstanding were 16.20 million. The filing reports 17.80 million common shares as of December 1, 2018.
- Principal risks: Clinical-trial outcomes, FDA review and approval, reliance on third-party manufacturers and research organizations, ability to raise capital, competition, reimbursement and market acceptance, intellectual-property protection, and potential equity dilution. The company had no product sales, a small workforce, and no internal sales or manufacturing infrastructure.
- The company reported no material litigation. Management said internal-control weaknesses identified in earlier years had been remediated and that controls were effective as of September 30, 2018.
Most important facts for investors to verify
- Current cash runway, operating cash burn, and financing needs relative to the going-concern warning and management’s June 2019 runway estimate.
- Phase 3 Mino-Lok enrollment, trial costs, interim-analysis outcomes, and whether results support the proposed regulatory pathway.
- CITI-002 development timing, FDA feedback, and funding priorities relative to the lead program.
- Fully diluted share count, warrant and option terms, and potential dilution from outstanding securities.
- Status and accounting treatment of the FDA refund and liability reversal, and any subsequent financing or material events.